Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.

Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 554, Suchdauer: 0.73s

12 3 4 5 6 7 8 9 10 11 weiter »

1
A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study

von Garrigós, L. ; Ruiz-Borrego, M. ; Pérez-García, J.M. ; et al.

In Annals of Oncology June 2026 37(6):837-848
- View full text via DOI
Merkliste

2
CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists’ perceptions

von Moreno, F. ; Iranzo, V. ; Álvarez, I. ; et al.

Clinical and Translational Oncology. 27(9):3819-3826
- Zum Volltext (via ReDI)
Merkliste

3
Non-coding RNAs as biomarkers and therapeutic targets in pancreatic cancer: Clinical implications and translational perspectives

von Carretero-Fernández, María ; Ruíz-Durán, Lucía ; Uysal-Onganer, Pinar ; et al.

In Biomedicine & Pharmacotherapy June 2026 199
- View full text via DOI
Merkliste

4
Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional characterization

von Galvez-Montosa F. ; Peduzzi G. ; Sanchez-Maldonado J. M. ; et al.

Schlagworte: autophagy; functional characterization; genetic variants; pancreatic cancer; polymorphisms; susceptibility
- View full text via BASE
Merkliste

5
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study

von Alés-Martínez, José Enrique ; Balmaña, Judith ; Sánchez-Rovira, Pedro ; et al.

In The Breast October 2024 77
- View full text via DOI
Merkliste

6
Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study

von Guerrero-Zotano, Á. ; Pérez-García, J.M. ; Ruiz-Borrego, M. ; et al.

In ESMO Open October 2024 9(10)
- View full text via DOI
Merkliste

7
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

8
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

9
200P Testing a higher dose (90 mg s.c.) of eftilagimod alpha, a soluble LAG-3 protein in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003

von Murillo, S. Morales ; Forget, F. ; Solis, E. Segui ; et al.

ESMO Open ; volume 9, page 103222 ; ISSN 2059-7029
- View full text via BASE
Merkliste

10
165P From bench to bedside: Functional domains of BRCA mutations for personalized medicine in breast cancer

von Torres-Mozas, P. ; Montosa, F. Galvez ; Sola, R. Arenas ; et al.

ESMO Open ; volume 9, page 103187 ; ISSN 2059-7029
- View full text via BASE
Merkliste

11
112MO Neoadjuvant study of 12 months of abemaciclib plus letrozole vs chemotherapy in HR+/HER2– highly proliferative (Ki67≥20%) breast cancer: CARABELA (GEICAM/2019-01) trial

von Jimenez, M. Martin ; Zotano, A.L. Guerrero ; Perez, M.E. ; et al.

ESMO Open ; volume 9, page 103100 ; ISSN 2059-7029
- View full text via BASE
Merkliste

12
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

13
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

14
AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization

von Duhoux, François ; Ibrahim, N ; Papadamitriou, K ; et al.

ESMO Open, Vol. 8, no.1, supplement 4, p. 101443 (2023)
- View full text via BASE
Merkliste

15
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

von von der Maase, H ; Hansen, S W ; Roberts, J T ; et al.

Journal of clinical oncology, Vol. 41, no.23, p. 3881-3890 (2023)
- View full text via BASE
Merkliste

16
153P Descriptive analysis of the location of point mutations in BRCA and the risk of breast or ovarian cancer diagnosis

von Torres-Mozas, P. ; Galvez Montosa, F. ; Luque Caro, N. ; et al.

Annals of Oncology ; volume 34, page S242 ; ISSN 0923-7534
- View full text via BASE
Merkliste

17
247P Efficacy of therapy directed against PI3K and cyclin inhibitors based on the location of PI3K mutations

von Torres-Mozas, P. ; Jimenez, A. Cano ; Cubero, R. Urbano ; et al.

ESMO Open ; volume 8, issue 1, page 101435 ; ISSN 2059-7029
- View full text via BASE
Merkliste

18
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

von Agajanian, Richy ; Ahmad, Rizvana ; Aktas, Bahriye ; et al.

In The Lancet Oncology April 2020 21(4):519-530
- View full text via DOI
Merkliste

19
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

20
134P Impact of pre-operative MammaPrint/BluePrint use for final treatment decisions in patients with stage II/IIIa HR+/HER2- early-stage breast cancer eligible for neoadjuvant chemotherapy: The DETERMIND study

von Marin-Liebana, S. ; Morales, S. ; Torres, A. Anton ; et al.

ESMO Open ; volume 8, issue 1, page 101473 ; ISSN 2059-7029
- View full text via BASE
Merkliste

21
146P Updated survival analysis in NEOPERSUR trial: Neoadjuvant pertuzumab in a real-world population in the south of Spain

von Gonzalez, A. Falcon ; Jurado, J. Cruz ; Valenti, E. Llabres ; et al.

ESMO Open ; volume 8, issue 1, page 101485 ; ISSN 2059-7029
- View full text via BASE
Merkliste

22
271P Eribulin (E) plus endocrine therapy (ET) in patients (pts) with HR[+]/HER2[-] metastatic breast cancer (mBC) after progression on previous ET: The REVERT study

von Lopez Gonzalez, A. ; Del Barco Berron, S. ; Garau Llinas, I. ; et al.

Annals of Oncology ; volume 33, page S661-S662 ; ISSN 0923-7534
- View full text via BASE
Merkliste

23
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).

von Albanell, J. ; Martínez-García, M. ; Ramos-Boyero, Manuel ; et al.

Schlagworte: Mamas - Cáncer - Tratamiento; Palbociclib; Fulvestrant; Endocrine-sensitive; Advanced breast cancer
- View full text via BASE
Merkliste

24
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.

von Martín, M ; Zielinski, C ; Ruiz-Borrego, M ; et al.

Schlagworte: CDK4/6 inhibitor; Capecitabine; Endocrine therapy; HER2–negative; Hormone receptor-positive metastatic breast cancer; Overall survival; Palbociclib; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Piperazines; Postmenopause; Pyridines; Receptor; ErbB-2; Receptors; Estrogen
- View full text via BASE
Merkliste

25
Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors-Health-EpiGEICAM Study

von Lope, V. ; Guerrero-Zotano, A. ; Ruiz-Moreno, E. ; et al.

Schlagworte: AS Coruña; CHUAC; INIBIC
- View full text via BASE
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag